ClinicalTrials.gg
TerminatedNCT03478293Updated Sep 9, 2022

iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications

An interventional study of iStent inject surgery in Primary Open Angle Glaucoma (POAG), sponsored by Glaukos Corporation. Terminated at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-09.

Sponsored by Glaukos Corporation · Not applicable, Interventional, and Treatment

Why this study was terminated
Business Decision

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.

Enrollment
38th of 38
6 · median 111
Started
2018
with 3 others
No phase
15 of 43
none open now
Registered
28th of 43
by date

Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 38th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 with no phase, and was the 28th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.

Read the detailed description

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications. Outcomes will be evaluated at 12 and 24 months.

03

Conditions studied

  • Primary Open Angle Glaucoma (POAG)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with primary open angle glaucoma (POAG)
  • Subject on two ocular hypotensive medications

Exclusion criteria

Exclusion Criteria:

  • Traumatic, uveitic, neovascular, or angle closure glaucoma
  • Fellow eye already enrolled
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    iStent inject surgery

    Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject

    Device: iStent inject surgery

Interventions

  • DeviceiStent inject surgery

    Micro-invasive glaucoma surgery (MIGS) to implant iStent inject

06

What researchers measure

Primary outcomes

  1. IOP reduction at 12 and 24 months on same number or fewer medications

    IOP reduction at 12 and 24 months on same number or fewer medications

    Time frame: 12 months and 24 months

07

Study locations

1 site
  • Department of Ophthalmology - UNIFESP/ Hospital São Paulo
    São Paulo, 04023-62, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Dec 2020, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2018
First posted
Mar 27, 2018
StartActual
Feb 27, 2018
Primary completionActual
Dec 30, 2020
CompletionActual
Dec 30, 2020
Last update
Sep 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03478293
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Feb 27, 2018
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020
Last update
Sep 9, 2022

Study contacts

Kerry Stephens, OD
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion